Home > Insider Trading > Filing (0001209191-19-048940)

Filing Details

Accession Number:: 0001209191-19-048940
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-09-09 18:27:27
Reporting Period:: 2019-09-05

Accepted Time:: 2019-09-09 18:27:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1660334	Verrica Pharmaceuticals Inc.	VRCA	Pharmaceutical Preparations (2834)	463137900

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1741937	Matt Davidson	C/O Verrica Pharmaceuticals Inc. 10 North High Street, Suite 200 West Chester PA 19380		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-09-05	3,100	$10.29	2,572,393	No	4	S	Direct
Common Stock	Disposition	2019-09-06	3,802	$10.38	2,568,591	No	4	S	Direct
Common Stock	Disposition	2019-09-06	4,712	$11.44	2,563,879	No	4	S	Direct
Common Stock	Disposition	2019-09-06	1,400	$12.07	2,562,479	No	4	S	Direct
Common Stock	Disposition	2019-09-09	6,300	$10.82	2,556,179	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.39 to $11.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.